Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Sep 4:8:104.
doi: 10.1186/s13045-015-0195-4.

Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia

Jingjing Wu  1 , Jiaping Fu  2 , Mingzhi Zhang  1 , Delong Liu  3   4
Affiliations
Review

Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia

Jingjing Wu et al. J Hematol Oncol. .

Abstract

Targeted therapy has been the forefront of cancer treatment. Cancer immunotherapy is the most recent focus. In addition, novel immunotherapeutics targeting B cell receptor signaling (e.g., ibrutinib), T cell receptor ( e.g., CART19), and NK cells (e.g., AFM13) are being developed. This review summarized the new development in blinatumomab (MT103/MEDI-538), a first-in-class bispecific T engager (BiTE) antibody against CD19/CD3 in patients with relapsed/refractory precursor B cell acute lymphoid leukemia.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Gene structure and production of bispecific blinatumomab diabody. DNA sequence of the CD19 heavy chain scFv (VHA) is connected with the CD3 light chain scFv (VLB) by a short linker (L) sequence to form a single gene encoding one peptide, VHA-VLB. By the same approach, the DNA sequence of the CD19 light chain scFv (VLA) is connected with the CD3 heavy chain scFv (VHB) by a short linker (L) sequence to form the second gene encoding the other peptide, VHB-VLA. The two polypeptide chains, VHA-VLB and VHB-VLA, can then heterodimerize non-covalently to form a diabody containing bispecific antigen-binding sites to both CD19 and CD3
Fig. 2
Fig. 2
Mechanism of action for blinatumomab as the first-in-class bispecific T cell engager (BiTE). One arm of blinatumomab binds to CD3, the other binds to CD19. This engages the unstimulated T cells which destroy the CD19+ cells
See this image and copyright information in PMC

References

    1. Akinleye A, Avvaru P, Furqan M, Song Y, Liu D. Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics. J Hematol Oncol. 2013;6(1):88. doi: 10.1186/1756-8722-6-88. - DOI - PMC - PubMed
    1. Akinleye A, Chen Y, Mukhi N, Song Y, Liu D. Ibrutinib and novel BTK inhibitors in clinical development. J Hematol Oncol. 2013;6(1):59. doi: 10.1186/1756-8722-6-59. - DOI - PMC - PubMed
    1. Akinleye A, Furqan M, Mukhi N, Ravella P, Liu D. MEK and the inhibitors: from bench to bedside. J Hematol Oncol. 2013;6(1):27. doi: 10.1186/1756-8722-6-27. - DOI - PMC - PubMed
    1. Furqan M, Akinleye A, Mukhi N, Mittal V, Chen Y, Liu D. STAT inhibitors for cancer therapy. J Hematol Oncol. 2013;6(1):90. doi: 10.1186/1756-8722-6-90. - DOI - PMC - PubMed
    1. Furqan M, Mukhi N, Lee B, Liu D. Dysregulation of JAK-STAT pathway in hematological malignancies and JAK inhibitors for clinical application. Biomarker Res. 2013;1(1):5. doi: 10.1186/2050-7771-1-5. - DOI - PMC - PubMed

Publication types

MeSH terms